We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App

Blocking the MicroRNA That Controls Angiogenesis Slows Breast Tumor Growth in a Diabetic Mouse Model

By LabMedica International staff writers
Posted on 20 Sep 2015
Print article
Image: Without angiogenesis a tumor cannot grow beyond a limited size (Photo courtesy of Wikimedia Commons).
Image: Without angiogenesis a tumor cannot grow beyond a limited size (Photo courtesy of Wikimedia Commons).
A team of molecular biologists demonstrated that it was possible to inhibit growth of breast tumors in a diabetic mouse model by injecting the animals with an antagonist of the microRNA (miRNA) that controls the process of angiogenesis (formation of new blood vessels).

Investigators at the Cleveland Clinic (OH, USA) had reported previously that angiogenesis in response to hyperglycemia in a cell- and tissue-specific manner was regulated by a novel pathway under the control of the microRNA miR-467. A microRNA is a member of the class of RNA fragments about 20 nucleotides long that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.

In the current study, the investigators examined whether systemic administration of an antagonist of miR-467 would prevent hyperglycemia-induced local angiogenesis in a tissue-specific manner. To this end they studied the effect of the antagonist on hyperglycemia-induced tumor growth and angiogenesis and on skin wound healing in mouse models of diabetes.

They reported in the September 2015 issue of the FASEB Journal that the systemic injection of the antagonist prevented hyperglycemia-induced angiogenesis and growth of mouse and human breast cancer tumors, where the miR-467 pathway was active in hyperglycemia. In tissues where the miR-467–dependent mechanism was not activated by hyperglycemia, there was no effect of the antagonist: the systemic injection did not affect skin wound healing or the growth of prostate tumors. The antagonist did not have any effect on organs or tissues unaffected by increased blood vessel growth.

"Complications of diabetes are the main reason for mortality and hospitalization of diabetic patients. The advanced methods of measuring and regulation of the blood sugar levels resulted in deaths from diabetic coma being very rare, but the vascular complications remain an important problem that leads to mortality and loss of quality of life," said Dr. Olga Stenina-Adognravi, a researcher in the department of molecular cardiology at the Cleveland Clinic. "Developing a new organ-specific way to prevent and treat the vascular complications and cancer growth in diabetic patients is the goal of our work."

Related Links:

Cleveland Clinic

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Auto Urinary Sediment Analyzer
Integrated Chemistry & Immunoassay System
Dimension RxL Max
Nucleic Acid Extraction System
Natch 48

Print article



view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio's Belgian Acquisition Targets Neurodegenerative Diagnostics

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.